Epstein-Barr Virus-Positive Lymphoproliferative Disorder in an HIV Patient Successfully Treated With Rituximab.

Alen G Karapetians, Tejasvi Ayyagari, Wilbur Montana

Abstract readCase Reports

In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alen G KarapetiansInternal Medicine and Hematology/Oncology, University of California, Los Angeles (UCLA) Kern Medical Center, Bakersfield, USA.

Tejasvi AyyagariInternal Medicine and Hematology/Oncology, University of California, Los Angeles (UCLA) Kern Medical Center, Bakersfield, USA.

Wilbur MontanaOncology, University of California, Los Angeles (UCLA) Kern Medical Center, Bakersfield, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs) represent a heterogeneous group of conditions that occur most often in immunocompromised individuals, including those with human immunodeficiency virus (HIV) infection, organ transplantation, autoimmune disease, and immune senescence. We report a case of a 55-year-old female with previously undiagnosed HIV, who presented with progressive throat pain, dysphagia, weight loss, and recurrent antibiotic-refractory tonsillitis, initially raising concern for squamous cell carcinoma. Imaging with contrast-enhanced CT of the neck revealed asymmetric oropharyngeal swelling with a rim-enhancing lesion, and biopsy demonstrated EBV-positive polymorphic LPD with clonal B-cell proliferation, confirmed by immunoglobulin heavy-chain gene rearrangement studies and Epstein-Barr virus-encoded RNA (EBER) in situ hybridization (EBER-ISH). Despite initiation of antiretroviral therapy and

Indexed as

ebv in hiv positiveebv positiveebv-positive b-cell lymphoproliferative diseaseebv-positive lymphoproliferative disorderebv-positive mucocutaneous ulcerebv ptldepstein-barr virus (ebv)rituximab monotherapyrituximab therapy

Identifiers

PMID41127741

DOI10.7759/cureus.92816

PMCPMC12538195

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.